# Expanded Clinical Study of the Tendyne Mitral Valve System

Study · id `cardio:ct-nct02321514` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02321514](<https://clinicaltrials.gov/study/NCT02321514>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02321514

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

## Technical summary

Registry record NCT02321514. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11 (actual); primary completion 2020-07 (actual). Results posted on 2021-09-02.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 191 participants (enrolled count; ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Started: 2014-11 (actual) (ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Primary completion: 2020-07 (actual) (ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Completion: 2025-04 (actual) (ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Results first posted: 2021-09-02 (ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Countries: United States; Australia; France; Germany; Italy; Netherlands; Norway; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT02321514, source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02321514-2025-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Expanded Clinical Study of the Tendyne Mitral Valve System
- Condition: Mitral Valve Regurgitation
- Intervention (Device): Tendyne Mitral Valve System
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 287b5105d95ed426b77e7a00d6ae394d196954505d68f8d667f17d0bde0b0c93
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
